Research output of the top 10 African countries : An analytical study

Ali, Waleed; Elbadawy, Ahmed

doi:10.1080/09737766.2021.1934181

Cited by 16 publications

(12 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, all the 10 most prolific researchers were affiliated with public institutions in South Africa, Tanzania and Botswana. Studies have consistently shown these African countries with substantial research output in Africa [41, 42]. Therefore, it is unsurprising that they also top the HPV research output.…”

Section: Discussionmentioning

confidence: 99%

“…Over 100 known types of HPVs, and they are grouped into non-carcinogenic and carcinogenic types [2]. The common noncarcinogenic types include HPV types 6,11,40,42,43,44 and 54; these HPV types atypically cause cancers [2,3], and typical examples of the diseases caused by them are papilloma, verruca, condyloma and focal epithelial hyperplasia (Heck's disease) [4]. On the other hand, the common carcinogenic types include HPV types 16,18,31,33,35,39 and 45 [2,3], and they are known for causing oropharyngeal, anal and genital cancers [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The state of human papillomavirus research in Africa

Kanmodi

Egbedina

Amzat

et al. 2023

Public Health Challenges

View full text Add to dashboard Cite

Background: Human papillomavirus (HPV) research scholarship evaluation is pivotal to the strategic planning, implementation and sustainability of HPV prevention and control programmes in Africa. Hence, this study evaluated HPV research scholarship in Africa. Methods: This review-a bibliometric analysis-investigated the trends, patterns, dynamics and funding of HPV-related literature production in Africa with a focus on the inequalities existing across thematic and subject areas, researchers, institutions and countries/territories/dependencies. The study data were obtained from SCOPUS database and analysed using the Microsoft Excel 2021 software. Result: From 1974 (inception year) till 16 July 2022, a total of 2587 SCOPUSindexed literature on HPV were produced by African authors, with an average production rate of 50.5 publications per year . A few publications (1.2%) were in the Social Sciences. Most (95.1%) publications were in English, only a few (3.9%) were in French, whereas none was in Arabic, Portuguese, Spanish, Swahili or any other official language of the African Union. South Africa, Nigeria and Egypt were the three most prolific African countries. The 10 most prolific researchers were affiliated to public institutions in South Africa, Tanzania and Botswana. The top 10 funding sponsors were public institutions in the United States, the United Kingdom, Belgium and South Africa. Moreover, researchers and institutions affiliated to South Africa, Nigeria, Kenya and Uganda were the predominant beneficiaries. Only two indigenous journals made the list of top 10 journals publishing HPV research outputs from Africa. Conclusion: Scholarly HPV research productivity in Africa is very low and worsened by multiple inequality gaps. There is an urgent need for equitably strengthening HPV research capacity in Africa.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The state of human papillomavirus research in Africa

Kanmodi

Egbedina

Amzat

et al. 2023

Public Health Challenges

View full text Add to dashboard Cite

show abstract

“…Overall, North African countries showed the highest growth in the country. Egypt has the highest number of indexed documents, H-index and the most cited documents with 67% of the total publications from 2015 to 2019, according to the Web of Science database [ 8 ]. Most papers are published in local or low-ranking journals.…”

Section: Discussionmentioning

confidence: 99%

What does it take to conduct clinical trials in African countries? Insights from Morocco

Benhima¹,

Fadli²,

Essâdi³

et al. 2022

ecancer

View full text Add to dashboard Cite

The progress on cancer diagnosis and treatment has attained, in the last decade, enormous achievements by any estimate. Immunotherapy, new generations of targeted therapies, Chimeric antigen T-cells, cancer vaccines and the fascinating breakthroughs in translational research and cancer biology have changed the direction of cancer care. However, the fact that all patients worldwide cannot have access to these advances is dramatic. Alongside this, taking part in clinical research is one way to improve and invest in cancer care. Patients from African—and most low-resources countries—are rarely offered the chance of being included in clinical trials. This well-known fact paints a disheartening picture of what having cancer is like in the poorest settings. This situation will further decline with population aging, major changes in risk profile imported from developed countries and life expectancy increasing in most African countries. If no radical changes are made, this North–South contrast will become more critical and continue to grow. Yet, there is room for hope because only when we acknowledge the problem can we begin to address it. We need a better understanding of the reasons behind this gap and to advocate for more representation from African patients in clinical trials, with respect to the socio-economic, epidemiological and unique demands of each country across the continent.

show abstract

“…This argument is not without merit, when one considers that South Africa, Egypt and Kenya, whose governments provide the greatest contribution to broad-spectrum research, innovation and infrastructure on the continent, are also responsible for the majority of African scientific outputs. [20][21][22][23] However, the fuller picture is linked to complex social, political and economic factors, where historically uneven development has a profound effect on access to experimental tools which would ordinarily be considered routine or even trivial in the global North.…”

Section: African Research and Visibilitymentioning

confidence: 99%

Biological and Medicinal Chemistry in Africa

et al. 2023

View full text Add to dashboard Cite

The young, fast‐growing population of Africa means that harnessing the economic benefits of scientific research is critical to sustained and equitable growth in the continent. Moreover, the whole world would benefit from the added intellectual contribution that would come from nurturing African science. The high burden of neglected diseases in Africa makes chemical biology a particularly important field. In this editorial, the reconvergence of science conducted at the interface of chemistry and biology is placed in the context of African participation, its importance to global science and the unique blend of supporting and hindering factors that influence African scientific contributions. The new Biological and Medicinal Chemistry in Africa special collection showcases a broad spectrum of African chemical biology.

show abstract

Research output of the top 10 African countries : An analytical study

Cited by 16 publications

References 11 publications

The state of human papillomavirus research in Africa

The state of human papillomavirus research in Africa

What does it take to conduct clinical trials in African countries? Insights from Morocco

Biological and Medicinal Chemistry in Africa

Contact Info

Product

Resources

About